Nymox Reports Near Completion of New Five Year Long-Term Follow-Up NX02-0014 U.S. Study of BPH Drug
June 15, 2010 09:50 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., June 15, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the Company is nearing completion of a new multi-center U.S. long-term...
Nymox to Present at Jefferies 2010 Global Life Sciences Conference
June 07, 2010 10:58 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., June 7, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that Paul Averback, MD, DABP, President and Chief Executive Officer of Nymox,...
New Positive Data on NX-1207 Presented at Symposium at American Urological Association Annual Meeting
June 02, 2010 09:15 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., June 2, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report on the presentation of new positive data at a high-level symposium and...
Nymox NX-1207 Symposium at American Urological Association Annual Meeting in San Francisco Tuesday June 1 at 3:00 p.m. PDT
May 27, 2010 12:17 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 27, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the presenters and participants for the symposium and panel discussion...
Nymox Announces 3 Year Follow-Up Results From NX02-0016 U.S. Study of NX-1207 for BPH
May 25, 2010 09:45 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 25, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report positive new results from the 30-36 month follow-up study of patients...
Symposium on Nymox's NX-1207 BPH Drug to be Held at Annual Meeting of American Urological Association in San Francisco
May 20, 2010 09:50 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 20, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that a symposium and panel discussion devoted to progress in the...
Nymox Nears Completion of New Three Year U.S. Long-Term Follow-Up Study of BPH Drug
May 18, 2010 10:00 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 18, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the Company is nearing completion of a new multi-center U.S. long-term...
Nymox Reports First Quarter 2010 Financial Results
May 14, 2010 09:37 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 14, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2010. Nymox reported a net loss...
Nymox Reports Positive Safety Monitoring Committee Update for Pivotal Phase 3 NX-1207 Trials
May 11, 2010 10:10 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 11, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational...
Nymox Announces Positive New Results in 6 Year Study of NX-1207 for Benign Prostatic Hyperplasia
May 04, 2010 10:10 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 4, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced new 2010 positive results from a long term outcome study of NX-1207 for benign...